Dakshina Kannada judge hasn't voted for last 32 years due to poll time transfers

Mangaluru, Mar 10: Four airports which are run by the Airport Authority of India (AAI), including Mangaluru International airport, have been adjudged among the best aerodromes in the world, winning 10 awards in four different categories at the 2019 ASQ awards.

ASQ is a globally established programme that measures passengers’ satisfaction while traveling through an airport. Airports Council International (ACI), which is an independent agency of airport operators, carries out international benchmarking of aerodromes.

“Four AAI airports — Chandigarh, Mangaluru, Trivandrum and Lucknow — have been adjudged the best in the world in recently announced 2019 ASQ awards. These airports won 10 awards in four categories,” Airports Authority of India (AAI) said in a release here on Tuesday.

The survey measures passengers’ satisfaction across 34 key performance indicators that include eight major categories such as access, check-in, security, airport facilities, food and beverage, retail, airport environment and arrival services.

The four categories in which these airports bagged the best airport awards were size and region, environment and ambiance, customer service and infrastructure and facilitation, as per the AAI.

The survey was carried out at across 356 airports across North America, Latin America and the Caribbean, Europe, Africa, the Middle East, and Asia.

The survey results are monitored by airport tariff regulator AERA, NITI Aayog, and civil aviation Ministry, the release added.

Bengaluru, Jun 5: An earthquake of magnitude 4.0 on the Richter Scale jolted Karnataka on Friday morning while another with a magnitude of 4.7 was felt in Jharkhand.

The tremors were felt in Hampi (Karnataka) and Jamshedpur (Jharkhand), according to the National Center for Seismology (NCS).

According to NCS, the aftershocks were felt at 6:55 am in both the places today.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.